Adial Pharmaceuticals, Inc.
ADIL
$0.2454
$0.00642.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.50% | -10.07% | -13.01% | -22.39% | -39.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.69% | 20.27% | 5.53% | -18.26% | -39.39% |
| Operating Income | -34.69% | -20.27% | -5.53% | 18.26% | 39.39% |
| Income Before Tax | 20.37% | -88.48% | -70.40% | -37.70% | -6.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.37% | -88.48% | -70.40% | -37.70% | -6.25% |
| Earnings from Discontinued Operations | -- | -- | -101.01% | -105.04% | 218.24% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.94% | -157.60% | -114.95% | -57.04% | 31.70% |
| EBIT | -34.69% | -20.27% | -5.53% | 18.26% | 39.39% |
| EBITDA | -34.69% | -20.28% | -5.53% | 18.26% | 39.38% |
| EPS Basic | 49.61% | 8.01% | 30.73% | 37.05% | 74.18% |
| Normalized Basic EPS | 56.50% | 21.65% | 43.91% | 43.62% | 47.25% |
| EPS Diluted | 49.61% | 8.10% | 30.78% | 37.08% | 74.19% |
| Normalized Diluted EPS | 56.50% | 21.65% | 43.91% | 43.62% | 47.25% |
| Average Basic Shares Outstanding | 202.35% | 239.95% | 248.05% | 150.67% | 85.80% |
| Average Diluted Shares Outstanding | 202.35% | 239.95% | 248.05% | 150.67% | 85.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |